Insulet Publishes 2022 Sustainability Report Focused on Innovating for the Future and Preserving the EnvironmentBusiness Wire • 05/02/23
Insulet Announces FDA Clearance of Omnipod GO™, a First-of-its-Kind Basal-Only Insulin Pod, Further Simplifying Life for People with Type 2 DiabetesBusiness Wire • 04/25/23
Option Trading: Insulet Butterfly Taps Into Stock's Leadership, Potential RallyInvestors Business Daily • 04/21/23
Insulet Joins S&P 500 And Gets Ready To Pump Up New Breakout With 56% GrowthInvestors Business Daily • 04/19/23
CORRECTING and REPLACING Insulet Reports Full Year 2022 Revenue Increase of 19% (22% constant currency1) and Fourth Quarter 2022 Revenue Increase of 20% Year-Over-Year (24% constant currency)Business Wire • 02/24/23
CORRECTING and REPLACING Insulet Reports Full Year 2022 Revenue Increase of 19% (22% constant currency1) and Fourth Quarter 2022 Revenue Increase of 20% Year-Over-Year (23% constant currency)Business Wire • 02/23/23
Insulet Reports Full Year 2022 Revenue Increase of 19% (22% constant currency1) and Fourth Quarter 2022 Revenue Increase of 20% Year-Over-Year (23% constant currency)Business Wire • 02/23/23
Highly Anticipated Omnipod® 5 Real-World Evidence to be Presented at the 16th International Conference on Advanced Technologies & Treatments for Diabetes (ATTD)Business Wire • 02/21/23
Insulet Acquires Insulin Pump Patents from Bigfoot Biomedical as Both Companies Prioritize Improved Insulin Delivery TechnologiesBusiness Wire • 02/13/23